Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

Hwan Mook Kim; Jaeseung Lim; Yeo Dae Yoon; Ji Mi Ahn; Jong Soon Kang; Kiho Lee; Song Kyu Park; Yu Jin Jeong; Jin Mi Kim; Gyoonhee Han; Kyu Hwan Yang; Yeon Jin Kim; Youngsoo Kim; Sang Bae Han

doi:10.1016/j.intimp.2007.08.007

Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

Hwan Mook Kim, Jaeseung Lim, Yeo Dae Yoon, Ji Mi Ahn, Jong Soon Kang, Kiho Lee, Song Kyu Park, Yu Jin Jeong, Jin Mi Kim, Gyoonhee Han, Kyu Hwan Yang, Yeon Jin Kim, Youngsoo Kim, Sang Bae Han

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

Cytokine-induced killer (CIK) cells are ex vivo expanded T cells with natural killer cell phenotypes and functions. In this study, the anti-tumor activity of CIK cells against hepatocellular carcinoma was evaluated in vitro and in vivo. In the presence of anti-CD3 antibody and IL-2 for 14 days, human peripheral blood mononuclear cell population changed to heterogeneous CIK cell population, which comprised 96% CD3⁺, 3% CD3^¡©CD56⁺, 32% CD3⁺CD56⁺, 11% CD4⁺, 75% CD8⁺, and 30% CD8⁺CD56⁺. CIK cells produced significant amounts of IFN-γ and TNF-α; however, produced only slight amounts of IL-2, IL-4, and IL-5. At an effector-target cell ratio of 30:1, CIK cells destroyed 33% of SNU-354 human hepatocellular carcinoma cells, which was determined by the ⁵¹Cr-release assay. In addition, a dose of 1 × 10⁶ CIK cells per mouse inhibited 60% of SNU-354 tumor growth in irradiated nude mice. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with hepatocellular carcinoma.

Original language	English
Pages (from-to)	1793-1801
Number of pages	9
Journal	International Immunopharmacology
Volume	7
Issue number	13
DOIs	https://doi.org/10.1016/j.intimp.2007.08.007
Publication status	Published - 2007 Dec 15

Bibliographical note

Funding Information:
This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1016/j.intimp.2007.08.007

Cite this

Kim, H. M., Lim, J., Yoon, Y. D., Ahn, J. M., Kang, J. S., Lee, K., Park, S. K., Jeong, Y. J., Kim, J. M., Han, G., Yang, K. H., Kim, Y. J., Kim, Y., & Han, S. B. (2007). Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. International Immunopharmacology, 7(13), 1793-1801. https://doi.org/10.1016/j.intimp.2007.08.007

@article{bb797e8f2d8e4b6fa026fb8a394adbc0,

title = "Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma",

abstract = "Cytokine-induced killer (CIK) cells are ex vivo expanded T cells with natural killer cell phenotypes and functions. In this study, the anti-tumor activity of CIK cells against hepatocellular carcinoma was evaluated in vitro and in vivo. In the presence of anti-CD3 antibody and IL-2 for 14 days, human peripheral blood mononuclear cell population changed to heterogeneous CIK cell population, which comprised 96% CD3+, 3% CD3¡{\textcopyright}CD56+, 32% CD3+CD56+, 11% CD4+, 75% CD8+, and 30% CD8+CD56+. CIK cells produced significant amounts of IFN-γ and TNF-α; however, produced only slight amounts of IL-2, IL-4, and IL-5. At an effector-target cell ratio of 30:1, CIK cells destroyed 33% of SNU-354 human hepatocellular carcinoma cells, which was determined by the 51Cr-release assay. In addition, a dose of 1 × 106 CIK cells per mouse inhibited 60% of SNU-354 tumor growth in irradiated nude mice. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with hepatocellular carcinoma.",

author = "Kim, {Hwan Mook} and Jaeseung Lim and Yoon, {Yeo Dae} and Ahn, {Ji Mi} and Kang, {Jong Soon} and Kiho Lee and Park, {Song Kyu} and Jeong, {Yu Jin} and Kim, {Jin Mi} and Gyoonhee Han and Yang, {Kyu Hwan} and Kim, {Yeon Jin} and Youngsoo Kim and Han, {Sang Bae}",

note = "Funding Information: This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).",

year = "2007",

month = dec,

day = "15",

doi = "10.1016/j.intimp.2007.08.007",

language = "English",

volume = "7",

pages = "1793--1801",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

number = "13",

}

TY - JOUR

T1 - Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

AU - Kim, Hwan Mook

AU - Lim, Jaeseung

AU - Yoon, Yeo Dae

AU - Ahn, Ji Mi

AU - Kang, Jong Soon

AU - Lee, Kiho

AU - Park, Song Kyu

AU - Jeong, Yu Jin

AU - Kim, Jin Mi

AU - Han, Gyoonhee

AU - Yang, Kyu Hwan

AU - Kim, Yeon Jin

AU - Kim, Youngsoo

AU - Han, Sang Bae

N1 - Funding Information: This research was partially supported by a grant from the KRIBB Research Initiative Program and by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (The Regional Research Universities Program/Chungbuk BIT Research-Oriented University Consortium).

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Cytokine-induced killer (CIK) cells are ex vivo expanded T cells with natural killer cell phenotypes and functions. In this study, the anti-tumor activity of CIK cells against hepatocellular carcinoma was evaluated in vitro and in vivo. In the presence of anti-CD3 antibody and IL-2 for 14 days, human peripheral blood mononuclear cell population changed to heterogeneous CIK cell population, which comprised 96% CD3+, 3% CD3¡©CD56+, 32% CD3+CD56+, 11% CD4+, 75% CD8+, and 30% CD8+CD56+. CIK cells produced significant amounts of IFN-γ and TNF-α; however, produced only slight amounts of IL-2, IL-4, and IL-5. At an effector-target cell ratio of 30:1, CIK cells destroyed 33% of SNU-354 human hepatocellular carcinoma cells, which was determined by the 51Cr-release assay. In addition, a dose of 1 × 106 CIK cells per mouse inhibited 60% of SNU-354 tumor growth in irradiated nude mice. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with hepatocellular carcinoma.

AB - Cytokine-induced killer (CIK) cells are ex vivo expanded T cells with natural killer cell phenotypes and functions. In this study, the anti-tumor activity of CIK cells against hepatocellular carcinoma was evaluated in vitro and in vivo. In the presence of anti-CD3 antibody and IL-2 for 14 days, human peripheral blood mononuclear cell population changed to heterogeneous CIK cell population, which comprised 96% CD3+, 3% CD3¡©CD56+, 32% CD3+CD56+, 11% CD4+, 75% CD8+, and 30% CD8+CD56+. CIK cells produced significant amounts of IFN-γ and TNF-α; however, produced only slight amounts of IL-2, IL-4, and IL-5. At an effector-target cell ratio of 30:1, CIK cells destroyed 33% of SNU-354 human hepatocellular carcinoma cells, which was determined by the 51Cr-release assay. In addition, a dose of 1 × 106 CIK cells per mouse inhibited 60% of SNU-354 tumor growth in irradiated nude mice. This study suggests that CIK cells may be used as an adoptive immunotherapy for patients with hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=35848932103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848932103&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2007.08.007

DO - 10.1016/j.intimp.2007.08.007

M3 - Article

C2 - 17996690

AN - SCOPUS:35848932103

SN - 1567-5769

VL - 7

SP - 1793

EP - 1801

JO - International Immunopharmacology

JF - International Immunopharmacology

IS - 13

ER -

Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this